Journal: bioRxiv

Article Title: Cardiac fibroblasts regulate cardiomyocyte hypertrophy through dynamic regulation of type I collagen

doi: 10.1101/2022.05.25.493406

Figure Lengend Snippet: (A) Whole ventricle mRNA microarray analysis of Col1a2 -/- mouse hearts compared to Col1a2 +/- at 2 months of age, n=3 per genotype. (B) Mass spectrometry analysis of ECM protein changes in Col1a2 -/- mouse hearts compared to Col1a2 +/- hearts at 3 months of age, n=4 per genotype. (C) Representative immunofluorescence images and (D) Western blot analysis of periostin from hearts of Col1a2 +/- and Col1a2 -/- mice at 3 months of age. Scale bar: 25 µm. (E) Flow cytometric gate strategy and (F) analysis of cardiac fibroblasts (MEFSK4 + /CD31 - /CD45 - ) from dissociated hearts of Col1a2 +/- and Col1a2 -/- mice at 3 months of age. (G) Representative immunofluorescence images of platelet-derived growth factor receptor (PDGFR)-α (purple) in Col1a2 +/- and Col1a2 -/- mice at 3 months of age. Wheat germ agglutinin (WGA) staining is green and shows outlines of cardiomyocytes. Scale bar: 100 µm. Relative mRNA expression of Col1a2 (H), Postn (I), Col3a1 (J) and Col5a1 (K) in sorted cardiac fibroblasts (MEFSK4 + /CD31 - /CD45 - ) from Col1a2 +/- and Col1a2 -/- mice at 9 months of age. Student t -test for panels (F), (H), (I), (J) and (K).

Article Snippet: Antibodies against the following proteins were used: periostin (Novus Biologicals NBP1-30042; 1:300 dilution for IF, 1:1000 for Western blot); collagen I (Abcam ab21286; 1:100 for IF); PDGFRα from (R&D Systems AF1062; 1:1000 for IF); collagen 1a2 (Santa Cruz sc-393573; 1:500 for Western blot) Anti-CD31 was from BioLegend (102423; 1:100 for flow cytometry); anti-CD45 was from BD Biosciences (563890; 1:100 for flow cytometry); anti-MEFSK4 was from Miltenyi Biotec (130-120-802; used 1:30 for flow cytometry).

Techniques: Microarray, Mass Spectrometry, Immunofluorescence, Western Blot, Derivative Assay, Staining, Expressing

Journal: Journal of Nanobiotechnology

Article Title: Nanoparticle-integrated smart hydrogel with H 2 S-triggered antibacterial escalation and sustained oxygen release for periodontal regeneration

doi: 10.1186/s12951-026-04535-7

Figure Lengend Snippet: Osteogenic differentiation of hPDLSCs induced by PDA@Hb/NOCG. ( A ) Representative ALP staining results of hPDLSCs after 7 days of osteogenic differentiation. ( B ) Alizarin Red S staining of hPDLSCs after 21 days of osteogenic induction. ( C ) Quantitative analysis of ALP staining in hPDLSCs. ( D ) Quantification of Alizarin Red S staining in hPDLSCs. ( E-K ) Relative mRNA expression levels of osteogenesis-related genes in hPDLSCs, including ALP, BMP2, COL1A1, OPG, RUNX2, OPN, and OCN, normalized to GAPDH. ( L-O ) Protein expression levels of osteogenesis-related markers in hPDLSCs, including ALP, RUNX2, and β-catenin, and their corresponding quantitative analysis. ( P ) Protein expression levels of osteogenesis-related markers, including ALP, RUNX2, and β-catenin, in hPDLSCs under different treatment conditions with or without DKK1. ( Q ) Corresponding quantitative analysis of ALP, RUNX2, and β-catenin protein expression in each group

Article Snippet: Primary antibodies against ALP (rabbit polyclonal IgG, Cat. No. 18507-1-AP), NF-κB p65 (rabbit polyclonal IgG, Cat. No. 10745-1-AP), and β-catenin (rabbit polyclonal IgG, Cat. No. 17565-1-AP) were purchased from Proteintech (Wuhan, China), while the antibodies against RUNX2 (rabbit polyclonal IgG, Cat. No. HY- P80316 ) and Hb (polyclonal antibody, Cat. No. PAB409Bo01) were obtained from MedChemExpress (MCE, Shanghai, China) and Cloud-Clone Corp. (Wuhan, China), respectively.

Techniques: Staining, Expressing